Nuclera
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · United Kingdom · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1 Vision Park Station Impington Rd, Camb...Phone Number
+44 1223625095Website
www.nuclera.comRevenue
$54.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
2
1
1
About Nuclera
Nuclera is the leading pioneer in making biology accessible through its eProtein desktop bioprinting technology. Headquartered in Cambridge, UK, Nuclera was founded in 2013 by four PhD students at the University of Cambridge who were frustrated by the inaccessibility of biology. With desktop bioprinting, researchers and scientists will be empowered to take control of biology through streamlined access to a next-day supply of proteins.Explore more
Nuclera Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nuclera your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Nuclera
Nuclera, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Nuclera is spiking on competitors!
Product Launch: Get notified when Nuclera launches new products
Funding: Get notified immidiatlly once Nuclera has new funding data
Click to see if Nuclera had a recent Job posting/layoffs
Check if Nuclera has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Nuclera recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Nuclera
Compare insights from companies similar to Nuclera, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Nuclera is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Nuclera is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Nuclera.
Nuclera financials insights
Gather financial insights about Nuclera, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$11.2M
2022
Series B
$58M
2024
Grant
$1.4M
Series C
$75M
2026
Series C
$12M
Nuclera Tech Stack
A closer look at the technologies used by Nuclera
Most Recent Scoops
Open Position
Open Position
Event
Events, Engineering, Sales, Bioengineering, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Operations
Person-Based
Partnership, Machine Learning, Medical Research, Pharmaceuticals, Artificial Intelligence
Funding
Funding
Nuclera News & Media
Nuclera extends Series C to $87 million to advance antibody engineering | The Pharmaletter
UK-based Nuclera, a biotech accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery System, has announced a $12 million financing extension, bringing the company’s total Series C funding to $87 million.Fresh $12m takes Nuclera Series C to $87m - Business Weekly
Cambridge biotech Nuclera has boosted its Series C round to $87 million after securing a further $12m from a range of backers.Nuclera extends Series C funding to $87M to accelerate antibody engineering work
Biotech company Nuclera has secured anadditional $12 million in financing, bringing its total Series C funding to $87million. The extension was led by Elevage Medical Technologies and JonathanMilner, ...Nuclera and Cytiva Collaborate to Accelerate Characterization of Proteins for Drug Development
CAMBRIDGE, England & MARLBOROUGH, Mass.--(BUSINESS WIRE)--Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ System, has announced a collaboration with Cytiva, a global life sciences leader. This collaboration is focused on accelerating the production, purification and characterization of proteins required for drug research and development, enabled through the combination of Nuclera’s eProtein Discovery System with Cytiva
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Nuclera
Sign Up For FreeTo access detailed company insights
Nuclera is the leading pioneer in making biology accessible through its eProtein desktop bioprinting technology. Headquartered in Cambridge, UK, Nuclera was founded in 2013 by four PhD students at the University of Cambridge who were frustrated by the inaccessibility of biology. With desktop bioprinting, researchers and scientists will be empowered... Read More
